Related Experiment Video

Updated: May 1, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Obstacles and opportunities in Alzheimer's clinical trial recruitment

Jennifer L Watson, Laurie Ryan, Nina Silverberg

    Health Affairs (Project Hope)
    |April 9, 2014
    PubMed

    Insights

    Recruiting volunteers for Alzheimer's disease clinical trials is crucial. Understanding barriers and forming community partnerships are key to increasing participation in Alzheimer's research.

    Area of Science:

    • Neuroscience
    • Clinical Research
    • Public Health

    Background:

    • The 2012 National Plan to Address Alzheimer's Disease aims for prevention and effective treatment by 2025.
    • Achieving this goal necessitates a significant increase in clinical trial participation.

    Purpose of the Study:

    • To explore barriers to Alzheimer's disease clinical trial recruitment.
    • To propose strategies for enhancing volunteer and healthcare provider engagement in Alzheimer's research.

    Main Methods:

    • Analysis of recruitment challenges specific to Alzheimer's studies.
    • Identification of potential solutions including consortiums and community partnerships.

    Main Results:

    • Understanding recruitment barriers is essential for mobilizing volunteers.
    • Innovative partnerships and effective outreach are vital for success.

    Conclusions:

    • Establishing a linked registry consortium can streamline recruitment.
    • Collaborating with community organizations can build trust and increase participation in Alzheimer's clinical trials.
    Keywords:
    Alzheimer’sClinical trialsRecruitment

    More Related Videos

    Transcranial Pulse Stimulation for Alzheimer's Patients06:08

    Transcranial Pulse Stimulation for Alzheimer's Patients

    Published on: April 4, 2025

    2.5K
    Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

    Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

    Published on: August 7, 2017

    7.5K

    Related Concept Videos

    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    1.3K
    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
    1.7K
    Alzheimer Disease l: Introduction01:29

    Alzheimer Disease l: Introduction

    Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
    21
    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    4.7K
    Clinical Trials01:16

    Clinical Trials

    Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
    There are four phases in a clinical trial. A phase one...
    8.5K
    Alzheimer Disease ll: Pathophysiology01:23

    Alzheimer Disease ll: Pathophysiology

    Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
    35